January 7, 2021 -- BrickBio has spun out a new Boston-based gene therapy company, EnCapsid, focused on developing enhanced adeno-associated virus (AAV) delivery vectors using technology that enables precise modification of AAV capsids and creating a new class of AAVs.
These novel AAVs will expand the number of treatable diseases and the cargo capacity of the AAV to allow for a more efficient CRIRSPR-Cas9 delivery vehicle.
EnCapsid's proprietary AAV engineering provides a flexible platform to precisely conjugate any entity onto a capsid, such as small molecules, peptides, nucleotides, and proteins (including antibodies). Moreover, the platform ensures selectivity of targeted delivery and cloaks the AAV against neutralizing antibodies while maintaining the fragile structure of the capsid.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
